Prescient Therapeutics Limited
ASX:PTX.AX
0.04 (AUD) • At close September 16, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Prescient Therapeutics Limited |
Symbool | PTX.AX |
Munteenheid | AUD |
Prijs | 0.041 |
Beurswaarde | 33,018,120 |
Dividendpercentage | 0% |
52-weken bereik | 0.037 - 0.105 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Steven Lee Yatomi-Clarke |
Website | https://ptxtherapeutics.com |
An error occurred while fetching data.
Over Prescient Therapeutics Limited
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (AUD)
Cijfers zijn in miljoenen (AUD)